Exagen Inc. (NASDAQ:XGN) Q2 2024 Earnings Call Transcript
Operator: Greetings. Welcome to the Exagen Inc. Second Quarter 2024 Earnings Call. At this time, all participants are in a listen-only mode.
Exagen Inc. (XGN)
Market is closed
Sector: Services-Medical Laboratories
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Stonepine Capital Timothy P. Lynch | 358,697 | $652,829 | -7% | 0.59% |
| 2. | Renaissance Technologies Jim Simons | 94,234 | $171,506 | +94% | 0% |
| 3. | Nantahala Capital Management Wilmot B. Harkey And Daniel Mack | 59,316 | $107,955 | -21% | 0% |
| 4. | Citadel Investment Group Ken Griffin | 25,379 | $46,190 | +251% | 0% |
| 5. | Millennium Management Israel Englander | 14,403 | $26,213 | -40% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.92 | 40,401 | Officer, Director | 40,401 | 2024-05-16 | Filing | |
| $3.11 | 167 | Large Shareholder | 1,515,839 | 2023-06-15 | Filing | |
| $2.68 | 90,000 | Officer, Director | 440,000 | 2022-12-08 | Filing | |
| $14.02 | 1,000 | Director | 1,000 | 2021-09-03 | Filing | |
| $14.00 | 425,000 | Large Shareholder | 1,696,252 | 2019-09-23 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.91 | 3,487 | Officer | 243,749 | 2024-03-04 | Filing | |
| $1.91 | 9,297 | Officer | 247,236 | 2024-03-04 | Filing | |
| $1.95 | 6,738 | Officer | 181,533 | 2024-02-06 | Filing | |
| $1.75 | 33,819 | Officer, Director | 415,984 | 2023-10-17 | Filing | |
| $2.30 | 3,667 | Officer | 188,271 | 2023-03-02 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 1,504,602 | $2,994,158 | 0.04% | |
| 2. | 898,630 | $1,788,273 | 0.11% | |
| 3. | 850,308 | $1,692,113 | 0% | |
| 4. | 544,877 | $1,084,305 | 0% | |
| 5. | 490,944 | $976,979 | 0% |
News See All
Exagen Inc. (NASDAQ:XGN) Q1 2024 Earnings Call Transcript
Operator: Greetings, welcome to Exagen, Inc. First Quarter 2024 Earnings Call. At this time, all participants are in listen-only mode.
Exagen Inc. (NASDAQ:XGN) Q4 2023 Earnings Call Transcript
Operator: Greetings. Welcome to Exagen Inc.’s Fourth Quarter 2023 Earnings Conference Call.
Exagen Inc. (NASDAQ:XGN) Q2 2023 Earnings Call Transcript
Operator: Greetings. Welcome to the Exagen Inc. Second Quarter 2023 Earnings Call. At this time, all participants are in a listen-only mode.
Exagen Inc. (NASDAQ:XGN) Q1 2023 Earnings Call Transcript
Operator: Good day, ladies and gentlemen, and welcome to the Exagen Q1 2023 Earnings Call. At this time, all participants are in a listen-only mode.
Exagen Inc. (NASDAQ:XGN) Q4 2022 Earnings Call Transcript
Operator: Greetings, and welcome to the Exagen Inc. Fourth Quarter Earnings Call. At this time, all participants are in a listen-only mode.
Do Hedge Funds Love Exagen Inc. (XGN)?
Like everyone else, elite investors make mistakes. Some of their top consensus picks, such as Amazon, Facebook and Alibaba, have not done well in Q4 of 2018 due to various reasons.
Billionaire Hedge Funds
